TMS|24144-92-1|((E)-2,3',4,5'-tetramethoxystilbene)-陌孚医药/Medlife

您当前的位置：

TMS (Synonyms: (E)-2,3',4,5'-tetramethoxystilbene)

目录号: PC12645 纯度: ≥98%

CAS No. :24144-92-1

商品编号	规格	价格	会员价
PC12645-5mg	5mg	¥646.80	请登录
PC12645-10mg	10mg	¥1034.88	请登录
PC12645-50mg	50mg	¥3880.80	请登录
PC12645-100mg	100mg	¥6232.80	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称

TMS

中文别名

(E)-1-(3,5-二甲氧基苯乙烯)-2,4-二甲氧基苯;2,3'',4,5''-四甲氧基二苯乙烯;2,3',4,5'-四甲氧基二苯乙烯;2,3,4,5-四甲氧基二苯乙烯

英文名称

TMS

英文别名

(E)-1-(3,5-Dimethoxystyryl)-2,4-dimethoxybenzene;(E)-2,3',4,5'-tetramethoxystilbene;2,4,3',5'-Tetramethoxystilbene;Benzene,1-[(1E)-2-(3,5-dimethoxyphenyl)ethenyl]-2,4-dimethoxy-;TMS;(E)-1-(2,4-dimethoxyphenyl)-2-(3,5-dimethoxyphenyl)ethene;(E)-2',3,4',5-tetramethoxystilbene;(E)-3,5,2',4'-tetramethoxystilbene;1-[(1E)-2-(3,5-DIMETHOXYPHENYL)ETHENYL]-2,4-DIMETHOXY-BENZENE;1-[2,(3,5-DIMETHOXYPHENYL)ETHENYL]-2;2,3',4,5'-tetramethoxy-trans-stilbene;2,4,3',5'-Tetramethoxy-trans-stilben;2,3′,4,5′-Tetramethoxystilbene;2,4,3′,5′-tetramethoxystilbene;1-[2-(3,5-Dimethoxyphenyl)ethenyl]-2,4-dimethoxybenzene;2,3',4,5'-tetramethoxystilbene;Cytochrome P450 1B1 Inhibitor, TMS;(E)-2,3′,4,5′-Tetramethoxystilbene;3,5,2',4'-tetramethoxy-trans-stilbene;1-[(E)-2-(2,4-dimethoxyphenyl)ethenyl]-3,5-dimethoxybenzene;Oxyresveratrol tetramethyl ether;1-[2,(3,5-Dimethoxyphenyl)ethenyl]-2,4-dimethoxybenzene;JDBCWSHYEQUBLW-AATRIKPK

Cas No.

24144-92-1

分子式

C₁₈O₄H₂₀

分子量

300.35

包装储存

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

生物活性

TMS ((E)-2,3,4,5-tetramethoxystilbene) is a selective and competitive CYP1B1 inhibitor with an IC₅₀ of 6 nM and a K_i value of 3 nM. TMS shows a lesser extent inhibitory effect on CYP1A1 (IC₅₀50[1].

性状

Solid

IC50 & Target[1][2]

CYP1B1

6 nM (IC₅₀)

CYP1A1

300 nM (IC₅₀)

CYP1A2

3.1 μM (IC₅₀)

CYP1B1

3 nM (Ki)

体外研究(In Vitro)

TMS, an analogue of resveratrol, is considered to be a potential cancer preventive agent since it is a potent inhibitor of CYP1B1. To assess survival of MCF-7 cells exposed to 1 μM benzo[a]pyrene (BP), 1 μM BP+1 μM TMS and 1 μM BP+4 μM TMS, cells ae incubated for up to 72 h without a media change. Luminescence units from exposed cells, expressed as a percentage of luminescence units from solvent (DMSO)-treated cells at the same time intervals. In all exposure groups, cell viability remains >90% for the first 24 h, but by 72 h, cell survival drops to 60-70%.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)

To determine the contribution of CYP1B1 in development of hypertension in spontaneously hypertensive rats (SHR), the effect of TMS is examined on in SHR and WKY rats. Systolic BP steadily increases in SHR from 4 weeks of age. Starting from 8 weeks of age, daily injections of TMS reduce systolic BP in SHR to levels observed at the beginning of the experiment (207±7 vs. 129±2 mmHg). Systolic BP is not altered in WKY injected with TMS or its vehicle (129±7 vs. 127±4 mmHg) .

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

运输条件

Room temperature or refrigerated transportation.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

参考文献

[1]. Sanghee Kim, et al. Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors. J Med Chem. 2002 Jan 3;45(1):160-4. [Information]

[2]. Einem Lindeman T, et al. The resveratrol analogue, 2,3,4,5-tetramethoxystilbene, does not inhibit CYP gene expression, enzyme activity and benzo[a]pyrene-DNA adduct formation in MCF-7 cells exposed to benzo[a]pyrene. Mutagenesis. 2011 Sep;26(5):629-35. [Information]

[3]. Jennings BL, et al. Cytochrome P450 1B1 contributes to increased blood pressure and cardiovascular and renal dysfunction in spontaneously hypertensive rats. Cardiovasc Drugs Ther. 2014 Apr;28(2):145-61. [Information]

溶解度数据

体外研究:

DMSO : ≥ 50 mg/mL (166.47 mM)

* "≥" means soluble, but saturation unknown.

配制储备溶液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.3294 mL	16.6472 mL	33.2945 mL
5 mM	0.6659 mL	3.3294 mL	6.6589 mL
10 mM	0.3329 mL	1.6647 mL	3.3294 mL

产品不同，其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液；配成溶液后，建议分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，建议在 6 个月内使用，-20°C 储存时，建议在 1 个月内使用。

体内研究:

建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 体外研究 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

建议依照次序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (8.32 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (8.32 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH?O 中，得到澄清透明的生理盐水溶液
2.

建议依照次序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (8.32 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (8.32 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation